Le Lézard
Classified in: Health
Subjects: LGB, DEI

The Fenway Institute: We must set a high bar for attributing psychopathology to sexual and gender minority people


Journal of Clinical Psychiatry commentary cautions against making assumptions that sexually and gender diverse people have a greater predisposition to psychiatric illness

BOSTON, July 22, 2022 /PRNewswire-PRWeb/ -- A commentary published July 18, 2022 in the Journal of Clinical Psychiatry cautions clinicians, scientists, and researchers against making assumptions that sexually and gender diverse people have a greater predisposition to psychiatric illness. The commentary was written in response to a newly published study by Oka et al showing that there were no differences in clinical responsiveness to electroconvulsive therapy (ECT) for treatment-resistant psychiatric illness between LGBTQ and non-LGBTQ patients. The authors of the study had hypothesized that LGBTQ patients would be less favorable to ECT because they would be more likely to have clinical conditions less favorable to ECT, such as posttraumatic stress disorder, personality disorders, or substance use disorders.

In "Psychiatric Care Considerations for Sexually and Gender Diverse Populations," commentary author Dr. Alex S. Keuroghlian, who directs the National LGBTQIA+ Health Education Center at The Fenway Institute and the Massachusetts General Hospital Psychiatry Gender Identity Program, observed that the premise of the study was flawed.

"When research on personality disorders among transgender and gender diverse people is closely examined, you will find wide variability not just in study settings and eligibility criteria, but also in gender identity data collection," Keuroghlian said.

While noting that external and internal stigma-related stressors can lead to increased risk of depressive, anxiety, posttraumatic stress, and substance use disorders among LGBTQ patients, Keuroghlian observed that the psychiatric field's historic response to these symptoms of minority stress has been to categorize sexual and gender diversity itself as psychopathology.

"This response has perpetuated stigma and discrimination toward sexually and gender diverse people in mental health care and even throughout society," Keuroghlian said. "In the context of escalating governmental attacks on the basic rights and health care access of sexually and gender diverse people, attribution of any psychopathology to sexually and gender diverse populations requires more analytic rigor, cautious deliberation, and nuanced contextualization than ever before."

Given that the main finding of the study by Oka et al was that patients have similar clinically significant improvement with ECT regardless of gender identity or sexual orientation, Keuroghlian concluded that ensuring equitable access to treatment for sexually and gender diverse people within welcoming and inclusive mental health care environments must be an imperative.

"Psychiatric Care Considerations for Sexually and Gender Diverse Populations," is available online.

Media Contact

Christopher Viveiros, Fenway Health, 617.927.6342, [email protected]

Twitter

 

SOURCE Fenway Health


These press releases may also interest you

at 22:00
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: